<DOC>
	<DOCNO>NCT01645930</DOCNO>
	<brief_summary>The purpose Phase 1 study characterize Pharmacokinetic ( PK ) tolerability Oral IXAZOMIB administer combination lenalidomide dexamethasone adult Asian patient Relapsed and/or Refractory Multiple Myeloma</brief_summary>
	<brief_title>Phase 1 Pharmacokinetic Study Oral IXAZOMIB Plus Lenalidomide Dexamethasone Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female East Asian patient 18 year old Diagnosed Multiple Myeloma accord standard criterion Measurable disease specify study protocol Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients relapse and/or refractory Multiple Myeloma receive 1 3 prior therapy Meet clinical laboratory criterion specify protocol Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree abstain heterosexual intercourse ; must also adhere guideline lenalidomide pregnancy prevention program Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse AND must adhere guideline lenalidomide pregnancy prevention program Must able take concurrent aspirin 325 mg daily Voluntary write consent Female patient lactate pregnant Major surgery radiotherapy within 14 day enrollment Infection require systematic antibiotic within 14 day study enrollment Central nervous system involvement Failure fully recover effect prior chemotherapy regardless interval since last treatment Systemic treatment strong inhibitor CYP1A2 , strong inhibitor CYP3A , strong CYP3A inducer , use Ginko biloba St. John 's wort within 14 day study enrollment Diagnosis Waldenstrom 's macroglobulinemia , POEMS syndrome , plasma cell leukemia , primary amyloidosis , myelodysplastic syndrome , myeloproliferative syndrome Evidence current uncontrolled cardiovascular condition Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol Known allergy study medication Known gastrointestinal condition procedure could interfere swallow oral absorption tolerance IXAZOMIB Diagnosed treat another malignancy within 2 year study enrollment previously diagnose another malignancy evidence residual disease exception nonmelanoma skin cancer completely resect carcinoma situ Ongoing active systemic infection , active hepatitis B virus infect , active hepatitis C infection , know human immunodeficiency virus ( HIV ) positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsed multiple myeloma ,</keyword>
	<keyword>Refractory multiple myeloma ,</keyword>
	<keyword>MLN9708 ,</keyword>
	<keyword>Proteasome inhibitor</keyword>
</DOC>